OncBioMune Pharmaceuticals, Inc. Announces Management Changes
June 11, 2020 at 05:29 pm EDT
Share
OncBioMune Pharmaceuticals, Inc. announced that Chief Executive Officer of Avant, Mick Ruxin, M.D., to serve as member of the Board of Directors, the Chairman of Avant, Jeffrey Busch, to serve as new Chairman and Yvonne Fors, a current member of the Board of Avant as a member of Board of Directors. Andrew Kucharchuk resigned from his position as President, will continue to serve the Company as a member of the Board of Directors. Dr. Jonathan Head resigned from his position as Chief Scientific Officer and from the Board of Directors. Daniel Hoverman, Charles Rice, Jr. and R. Neal Holcomb resigned from the Board of Directors.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
THERALINK TECHNOLOGIES, INC. 